People
Moderna has fully enrolled its late-stage coronavirus disease 2019 (COVID-19) vaccine trial by hitting its target of 30,000 participants. More than one-third of this cohort includes minority participants.
After reviewing its mid-pandemic performance, it became clear that its greatest challenge is around the handling of data, according to Amy P. Abernethy, M.D., Ph.D., principal deputy commissioner, FDA, speaking at the recent Demy-Colton Virtual Salon, the “Fusion of Technologies.”
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
It’s a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
October is Breast Cancer Awareness month, and Daiichi Sankyo is aiming to raise awareness about one of the most common forms of cancer across the globe.
As we resign ourselves to the fact that the epic SARS-CoV-2 virus that dominated 2020 is going to stubbornly follow us into 2021, we need to learn how to co-exist in temporary tolerance, at least until we have an effective vaccine.
Dr. Monica Gandhi, MD, an infectious diseases doctor and professor of medicine at UC San Francisco, poses the hypothesis that masks and other social distancing measures may reduce the viral inoculum – or amount – of the SARS-CoV-2 we contract.
Immuno-oncology and CAR T cells energized the field of regenerative medicine, but for cell and gene to deliver on their promises, new, disruptive technologies and new modes of operation are needed.
By using naturally-derived scaffolds, human cells and other biocompatible materials, 3D bioprinting has ushered in opportunities for researchers to design, print and optimize patient personalized tissues for purposes ranging from transplantation to drug testing.
PRESS RELEASES